Medicare Enrolled
Dr. Tony Tsai, M.D.
Ophthalmology · Sacramento, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tsai from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tsai?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tsai
Dr. Tony Tsai is an ophthalmology specialist in Sacramento, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Tsai performed 53,256 Medicare services across 5,447 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tsai received a total of $3,246 from 20 pharmaceutical and/or device companies across 65 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tsai is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in CA
$3,246 industry payments
Medicare Practice Summary
Medicare Utilization ↗53,256
Medicare services
Top 1% in CA for ophthalmology
5,447
Unique beneficiaries
$74
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,803 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) An injection of faricimab-svoa, a medication administered in 0.1 mg doses. |
38,580 | $29 | $80 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
3,454 | $31 | $150 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
2,058 | $99 | $1,147 |
| Aflibercept eye injection (Eylea) | 2,022 | $688 | $1,792 |
| Ranibizumab-nuna biosimilar injection, 0.1 mg An injection of the biosimilar medication ranibizumab-nuna (Byooviz) at a dose of 0.1 mg. |
1,455 | $173 | $500 |
| Comprehensive eye exam, established patient A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider. |
1,105 | $93 | $450 |
| Ranibizumab-eqrn injection, 0.1 mg An injection of the biosimilar medication ranibizumab-eqrn (Cimerli) in a 0.1 mg dose. |
917 | $219 | $670 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
522 | $69 | $328 |
| Pegcetacoplan intravitreal injection, 1 mg An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram. |
450 | $120 | $310 |
| Injection, ranibizumab, 0.1 mg | 383 | $184 | $531 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
329 | $117 | $494 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
327 | $65 | $310 |
| Dexamethasone intravitreal implant injection An injection of a dexamethasone implant placed inside the eye. This procedure delivers medication directly into the vitreous cavity of the eye. |
294 | $159 | $363 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
253 | $97 | $439 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
174 | $28 | $138 |
| Ultrasound of eye tissue and structures A non-invasive imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
146 | $55 | $249 |
| Compounded drug, not otherwise classified A medication prepared specifically for an individual patient by a pharmacist or physician, tailored to meet unique needs that cannot be fulfilled by commercially available products. |
122 | $71 | $550 |
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
114 | $39 | $181 |
| Extended eye exam with retinal drawing A detailed examination of the back of the eye that includes creating a drawing of the retina. |
114 | $19 | $89 |
| Comprehensive eye exam, new patient A comprehensive examination of the visual system performed for a new patient. |
106 | $115 | $525 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
95 | $125 | $565 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
74 | $1,859 | $8,243 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
35 | $72 | $380 |
| Retinal laser treatment for leaking blood vessels This procedure uses a laser to seal leaking blood vessels in the retina. It is performed to prevent vision loss caused by fluid leakage from damaged retinal vessels. |
20 | $263 | $1,451 |
| Retinal detachment repair with fluid drainage A surgical procedure to reattach a detached retina by draining excess fluid from the space between the lens and the retina. |
19 | $1,003 | $4,996 |
| Retinal photocoagulation to prevent detachment This procedure uses laser light to create small burns on the retina. It is performed to help prevent the retina from detaching from the back of the eye. |
19 | $207 | $1,121 |
| Ultrasound of eye using water bath method An ultrasound imaging test of the eye that uses a water bath technique to visualize internal eye structures. |
19 | $62 | $295 |
| Retinal membrane and internal limiting membrane removal A surgical procedure to remove a membrane from the retina along with the internal limiting membrane of the retina. |
16 | $964 | $4,741 |
| Extended exam of back of eye with optic nerve drawing A detailed examination of the posterior section of the eye, including the optic nerve, with documentation through drawing. |
12 | $11 | $60 |
| Removal of retinal membrane A surgical procedure to remove a membrane from the surface of the retina. |
11 | $962 | $4,797 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
11 | $34 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$3,246
Total received (2018-2024)
Avg $464/year across 7 years
Top 33% in CA for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
20
Companies
65
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,246 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$798
2023
$770
2022
$213
2021
$165
2020
$193
2019
$713
2018
$395
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$213
Apellis Pharmaceuticals, Inc.
$172
Regeneron Healthcare Solutions, Inc.
$158
Astellas Pharma US Inc
$114
Alcon Vision LLC
$102
Alimera Sciences, Inc.
$26
Ocular Therapeutix, Inc.
$14
Top 3 companies account for 68.1% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$626
Apellis Pharmaceuticals, Inc.
$534
Alcon Vision LLC
$382
Alimera Sciences, Inc.
$305
Astellas Pharma US Inc
$211
Regeneron Healthcare Solutions, Inc.
$211
Mallinckrodt Hospital Products Inc.
$144
Genentech, Inc.
$122
Aerie Pharmaceuticals, Inc.
$115
Biogen, Inc.
$113
Novartis Pharmaceuticals Corporation
$108
Johnson & Johnson Vision Care, Inc.
$102
AbbVie, Inc.
$87
Dutch Ophthalmic, USA
$41
Carl Zeiss Meditec AG
$39
Pacira Pharmaceuticals Incorporated
$32
Bausch & Lomb Americas Inc.
$23
Allergan Inc.
$22
Ocular Therapeutix, Inc.
$14
NotalVision
$13
Top 3 companies account for 47.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · Acuvue · BEOVU · BROLUCIZUMAB · Constellation · DEXTENZA · EVA · EYLEA · ForeseeHome · HYDRUS Microstent · Humira · ILUVIEN · Iluvien · Iovera System · Izervay · Lucentis · None Specified · OZURDEX · SUSVIMO · Susvimo · Syfovre · VABYSMO · Vabysmo · XIPERE · YUTIQ · combined machine · rocklatan
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Ophthalmologists within 10 mi
144
Per 100K population
9.1
County median income
$88,724
Nearest hospital
MERCY GENERAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tsai is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tsai experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Tsai performed 38,580 eye injection (vabysmo/faricimab) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tsai receive payments from pharmaceutical companies?
Yes. Dr. Tsai received a total of $3,246 from 20 companies across 65 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tsai's costs compare to other ophthalmologists in Sacramento?
Dr. Tsai's average Medicare payment per service is $74. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tsai) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Ophthalmologists in Sacramento
Browse ophthalmologists in Sacramento ranked by procedure volume and transparency data.
Highest volume
Top Ophthalmologists in CA
Ophthalmologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Ophthalmologists in CA
Which CA ophthalmologists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Apellis Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Apellis Pharmaceuticals, Inc.
By company
Alcon Vision LLC Payments to Doctors
See all physicians who received payments from Alcon Vision LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology